Results 281 to 290 of about 157,760 (344)

Impact of aldosterone deficiency on the development of diuretic resistance in mice. [PDF]

Pflugers Arch
Essigke D, Kalo MZ, Janessa A, Bohnert BN, Li X, Birkenfeld AL, Artunc F.   +6 more
europepmc   +1 more source

The Utility of Plasma Metanephrines to Optimise Adrenal Vein Sampling for Primary Aldosteronism: A Single Centre Experience

Clinical Endocrinology, EarlyView.
ABSTRACT Background Primary aldosteronism (PA) is a prevalent yet frequently underdiagnosed cause of secondary hypertension, affecting up to 10% of hypertensive individuals and contributing to increased cardiovascular risk. Accurate diagnosis is vital, as unilateral PA cases typically require surgical intervention, while bilateral disease is managed ...
Zin Htut, Ali Alsafi, Aditi Sharma, Daniel Foran, Tricia Tan, Sophie C. Barnes, Emma L. Williams, Debbie Papadopoulou, Aimee Dimarco, Fausto Palazzo, Jeannie Todd, Rami Fikri, John Wass, Karim Meeran, Florian Wernig   +14 more
wiley   +1 more source

Novel predictive factors scoring model for persistent hypertension after adrenalectomy in patients with primary aldosteronism. [PDF]

Sci Rep
Harirugsakul K, Suharitdumrong S, Panumatrassamee K, Ratchanon S, Usawachintachit M, Sowanthip D, Pobpan P, Sainont G, Santingamkun A.   +8 more
europepmc   +1 more source

Ramadan Fasting Improves Health‐Related Quality of Life in Patients With Secondary Adrenal Insufficiency: A Prospective Interventional Case‐Control Study

Clinical Endocrinology, EarlyView.
ABSTRACT Introduction Intermittent fasting (IF) exposes patients with adrenal insufficiency (AI) to complications related to undertreatment. We aimed to determine the effect of IF during Ramadan on the quality of life of patients with secondary adrenal insufficiency (SAI) compared to healthy controls.
Mariam Mabrouk, Melika Chihaoui, Jameleddine Sta, Chayma Belhadj Slimane, Ibtissem Oueslati, Meriem Yazidi, Fatma Chaker   +6 more
wiley   +1 more source

Screening for primary aldosteronism in 1,181 Swedish primary care patients with hypertension. [PDF]

Front Endocrinol (Lausanne)
Makhnov N, Skov J, Åkerström T, Axling F, Andernord D, Bergenheim M, Waldén M, Hellman P.   +7 more
europepmc   +1 more source

Effect of glucagon‐like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta‐analysis

Clinical Obesity, Volume 15, Issue 4, August 2025.
Summary The effect of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) on systolic blood pressure (SBP) in patients with obesity with or without diabetes remains unclear. The aim was to compare the effect of different drug–dose combinations of GLP‐1RAs on SBP.
Abraish Ali, Asad Ali Siddiqui, Muhammad Shariq Usman, Izza Shahid, Muhammad Shahzeb Khan, Prinka Perswani   +5 more
wiley   +1 more source

Apparent Mineralocorticoid Excess Syndrome: Case Report. [PDF]

Int Med Case Rep J
Alsaadoun SA, Alrasheedi AT, Gazar SH, Alsallum GA.   +3 more
europepmc   +1 more source

Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease—A practical update for clinicians

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Albuminuria, the abnormal presence of albumin in urine, is a key marker of kidney damage and a strong predictor of kidney and cardiovascular outcomes. Its clinical significance has evolved from early historical observations to its current role in chronic kidney disease (CKD) detection, risk stratification and treatment monitoring.
Jelle M. Beernink, Dominique van Mil, Gozewijn D. Laverman, Hiddo J. L. Heerspink, Ron T. Gansevoort   +4 more
wiley   +1 more source

Can Statistical Data Replace Pathophysiologic Rationale?: A Belated Question for the Second Quarter of the 21st Century. [PDF]

Am J Med Open
Perk M.
europepmc   +1 more source

Use of NT‐proBNP for the screening, diagnosis and risk‐stratification of left ventricular dysfunction

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Heart failure (HF) is a major health problem, and preventing the onset of heart failure could have large cost implications for healthcare systems globally. Screening for heart failure and its precursor, left ventricular dysfunction, could allow patients to receive therapies shown to reduce the risk of incident heart failure, such as ACE ...
Pardeep S. Jhund
wiley   +1 more source